Buy CryptoMarketsSpotFuturesIOSTEarnEvent CenterRewards Hub
More
Sign Up
MEXC Exchange/Learn/Sarah Chen
Sarah Chen

Sarah Chen

Nationality: Australia Bio: Sarah Chen specializes in DeFi protocols, smart contracts, and Layer-2 solutions. Based in Melbourne, she brings technical expertise and clear communication to complex blockchain topics. She holds a Bachelor's degree in Computer Science from the University of Melbourne and worked as a blockchain developer for three years before transitioning to technical writing. Her hands-on experience with Ethereum, Solana, and other platforms allows her to explain intricate concepts in accessible language. Since joining MEXC Learn in 2022, Sarah has focused on making blockchain technology understandable for all users, covering topics from DeFi yield farming to zero-knowledge proofs. Areas of Expertise: - DeFi Protocols - Smart Contract Analysis - Layer-2 Solutions - Blockchain Infrastructure - Protocol Security

Recent Articles

MRKON Risks Explained: KEYTRUDA Dependence, Patent Expiry, Clinical Trials and Tokenized Stock Risk

MRKON Risks Explained: KEYTRUDA Dependence, Patent Expiry, Clinical Trials and Tokenized Stock Risk

Summary MRKON combines the risks of a major pharmaceutical company with an additional tokenized-market layer. The most important underlying risks include: dependence on KEYTRUDA; the 2028 patent

2026-09-10

Is MRKON Backed by MRK Stock? Custody, Dividends and Investor Rights Explained

Is MRKON Backed by MRK Stock? Custody, Dividends and Investor Rights Explained

Summary MRKON belongs to Ondo Stocks, a tokenized-equities framework designed to provide economic exposure to traditional securities. Ondo describes its tokenized stocks as total-return trackers of

2026-09-10

Can Merck Grow Beyond KEYTRUDA? WINREVAIR, KEYTRUDA QLEX and the Next-Generation Pipeline

Can Merck Grow Beyond KEYTRUDA? WINREVAIR, KEYTRUDA QLEX and the Next-Generation Pipeline

Summary Merck's biggest strategic question is increasingly straightforward: Can the company build enough new growth before conventional KEYTRUDA faces significant loss-of-exclusivity pressure? The

2026-09-10

Merck and Moderna's Cancer Vaccine Explained: What the Phase 3 Breakthrough Means for MRKON

Merck and Moderna's Cancer Vaccine Explained: What the Phase 3 Breakthrough Means for MRKON

Summary Merck and Moderna announced a major Phase 3 clinical milestone on August 19, 2026. The INTerpath-001 trial evaluating intismeran autogene plus KEYTRUDA in patients with completely resected

2026-09-10

Merck's KEYTRUDA Patent Cliff Explained: What 2028 Could Mean for MRK and MRKON

Merck's KEYTRUDA Patent Cliff Explained: What 2028 Could Mean for MRK and MRKON

Summary KEYTRUDA is Merck's most important drug franchise and one of the world's largest pharmaceutical products. Merck's 2025 Form 10-K lists 2028 as the U.S. compound-patent expiration for

2026-09-10

What Drives MRKON Price? KEYTRUDA, WINREVAIR, Earnings and Merck Stock Explained

What Drives MRKON Price? KEYTRUDA, WINREVAIR, Earnings and Merck Stock Explained

Summary MRKON price is fundamentally linked to MRK, the common stock of Merck & Co. That means the most important price drivers are pharmaceutical rather than crypto-native. Today, investors should

2026-09-10

MRKON vs MRK: What's the Difference Between Tokenized Merck and Merck Stock?

MRKON vs MRK: What's the Difference Between Tokenized Merck and Merck Stock?

Summary MRK and MRKON both provide exposure connected to Merck & Co., Inc., but they are not the same financial instrument. MRK is Merck's common stock listed on the New York Stock Exchange. MRKON,

2026-09-10

What Is MRKON? A Complete Guide to Merck (Ondo Tokenized Stock)

What Is MRKON? A Complete Guide to Merck (Ondo Tokenized Stock)

Summary MRKON, also styled MRKon, is an Ondo tokenized-stock product designed to provide economic exposure linked to Merck & Co., Inc. common stock, which trades on the New York Stock Exchange under

2026-09-09

MRVLON Risks Explained: AI Expectations, Customer Concentration, Tracking and Liquidity

MRVLON Risks Explained: AI Expectations, Customer Concentration, Tracking and Liquidity

Summary MRVLON combines two major risk categories. The first comes from Marvell itself: AI demand; hyperscaler spending; custom-silicon execution; customer concentration; semiconductor competition;

2026-09-09

Is MRVLON Backed by MRVL Stock? Custody, Dividends and Investor Rights Explained

Is MRVLON Backed by MRVL Stock? Custody, Dividends and Investor Rights Explained

Summary MRVLON belongs to Ondo Stocks, a tokenized-equities framework designed to provide economic exposure linked to traditional securities. Ondo states that its tokenized stocks are backed by

2026-09-09

Related author

James Mitchell
James Mitchell
Marcus O'Brien
Marcus O'Brien
MEXC
MEXC
Emma Williams
Emma Williams